(VIANEWS) – SPBK1 ØSTFOLD AKE (SOAG.OL), SPBK1 NORD-NORGE (NONG.OL), NAVAMEDIC (NAVA.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. SPBK1 ØSTFOLD AKE (SOAG.OL)
36.1% sales growth and 11.66% return on equity
SpareBank 1 Østfold Akershus, a savings bank, provides various banking products and services in Østfold and the southern part of Akershus. The company offers savings, operating, tax deduction, deposit, placement, and currency accounts; and savings and investment products. It also provides consumer, construction, repayment, boat, motorcycle, and car loans; operating credit products; bank guarantees; liquidity loans with government guarantees; operating credit for agriculture; mortgage products; leasing and factoring services; and refinancing services. In addition, the company offers various insurance products, such as vehicle, house and travel, personal, animal, liability, work machine, interruption, condominium, cyber, truck, movable property, commercial building, project, transport, crime, bus, group life, health, leisure accident, occupational injury, accident insurance children, and sick pay insurance products; and pension products. Further, it provides credit, municipal payment, and other bank cards; payment terminal, debt collection, and document collection services; bonds, forwards, and currency options; accounting approved, invoice automatic, eGiro/Cremul, KID invoice, and OCR and eGiro payment services; and mobile and online banking services. The company was founded in 1835 and is headquartered in Moss, Norway.
Earnings Per Share
As for profitability, SPBK1 ØSTFOLD AKE has a trailing twelve months EPS of kr35.74.
PE Ratio
SPBK1 ØSTFOLD AKE has a trailing twelve months price to earnings ratio of 8.62. Meaning, the purchaser of the share is investing kr8.62 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.66%.
Sales Growth
SPBK1 ØSTFOLD AKE’s sales growth is 29.2% for the ongoing quarter and 36.1% for the next.
More news about SPBK1 ØSTFOLD AKE.
2. SPBK1 NORD-NORGE (NONG.OL)
30.3% sales growth and 13.71% return on equity
SpareBank 1 Nord-Norge provides banking services in Northern Norway. It operates through Retail Market, Corporate Market, Leasing, and Markets segments. The company offers mortgage, car, vehicle, and other loan related services. It also offers vehicle, home, travel, personal, and pet insurance services. In addition, the company provides various savings and pension related services, as well as debit and credit card services. Further, it offers financing, real estate leasing, agency, payment, and investment services. The company was founded in 1836 and is headquartered in Tromsø, Norway.
Earnings Per Share
As for profitability, SPBK1 NORD-NORGE has a trailing twelve months EPS of kr9.47.
PE Ratio
SPBK1 NORD-NORGE has a trailing twelve months price to earnings ratio of 10.23. Meaning, the purchaser of the share is investing kr10.23 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.71%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is 110.6% and a drop 22.6% for the next.
Sales Growth
SPBK1 NORD-NORGE’s sales growth is 66.9% for the present quarter and 30.3% for the next.
Yearly Top and Bottom Value
SPBK1 NORD-NORGE’s stock is valued at kr96.90 at 07:20 EST, below its 52-week high of kr103.60 and way above its 52-week low of kr78.10.
More news about SPBK1 NORD-NORGE.
3. NAVAMEDIC (NAVA.OL)
22.8% sales growth and 22.97% return on equity
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, obesity, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NAVAMEDIC has a trailing twelve months EPS of kr1.73.
PE Ratio
NAVAMEDIC has a trailing twelve months price to earnings ratio of 21.1. Meaning, the purchaser of the share is investing kr21.1 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.97%.
Sales Growth
NAVAMEDIC’s sales growth is 11.5% for the present quarter and 22.8% for the next.
Volume
Today’s last reported volume for NAVAMEDIC is 794 which is 97.22% below its average volume of 28604.
Yearly Top and Bottom Value
NAVAMEDIC’s stock is valued at kr36.50 at 07:20 EST, way under its 52-week high of kr43.60 and way above its 52-week low of kr27.80.
Revenue Growth
Year-on-year quarterly revenue growth grew by 93.3%, now sitting on 440.93M for the twelve trailing months.
More news about NAVAMEDIC.
4. KITRON (KIT.OL)
16.8% sales growth and 29.51% return on equity
Kitron ASA operates as an electronics manufacturing services company in Norway, Sweden, rest of Europe, the United States, and internationally. It manufactures electronics that are embedded in the customers' products; and box-built electronic products. The company's services include development services, such as product development, product management, and re-engineering services; and industrialization services, including prototype manufacturing, evaluation of new products, component engineering and database, test development, design and build of high level assembly lines, and environmental durability testing. Its services also comprise sourcing and procurement services; manufacturing, assembling, and testing of electronic products for the professional market; redesign, repair, and maintenance; and logistics and distribution services. The company was incorporated in 1996 and is headquartered in Billingstad, Norway.
Earnings Per Share
As for profitability, KITRON has a trailing twelve months EPS of kr2.52.
PE Ratio
KITRON has a trailing twelve months price to earnings ratio of 14.74. Meaning, the purchaser of the share is investing kr14.74 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.51%.
More news about KITRON.
5. MAREL (MAREL.AS)
5.5% sales growth and 4.51% return on equity
Marel hf. develops, distributes, and sells solutions, software, and services to food processing industries in Europe, the Middle East, Africa, the Americas, Asia, and Oceania. The company's Poultry Processing segment offers integrated systems, software, and services for processing broilers, turkeys, and ducks. Its Meat Processing segment supplies primary, secondary, and further processing equipment, systems, software, and services of pork, beef, veal, and sheep. The company's Fish Processing segment offers equipment, systems, software, and services for farmed and wild salmon and whitefish processing. Its Plant, pet and feed segment provides solutions and services to the pet food, plant-based protein, and aqua feed markets. Marel hf. was founded in 1977 and is based in Garðabær, Iceland.
Earnings Per Share
As for profitability, MAREL has a trailing twelve months EPS of €0.06.
PE Ratio
MAREL has a trailing twelve months price to earnings ratio of 50.5. Meaning, the purchaser of the share is investing €50.5 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.51%.
More news about MAREL.
